Literature DB >> 10050985

Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.

G Bacci1, P Picci, M Mercuri, S Ferrari, A Longhi, M Cesari, P Rosito, A F Mancini, E Barbieri, N Baldini.   

Abstract

Clinicopathologic variables associated with a good histological response to primary chemotherapy in Ewing's sarcoma are identified. The histological response to preoperative chemotherapy in 243 cases of Ewing's sarcoma treated with neoadjuvant chemotherapy was analyzed in relation to different clinicopathological features (sex and age of the patients, tumor size, serum lactate dehydrogenase (LDH) levels, tumor site) and to the type and schedule of anticancer drugs delivered preoperatively according to three consecutive chemotherapy regimens. A higher rate of good responses was achieved with the use of ifosfamide and dactinomycin in addition to a conventional three-drug VAC regimen, suggesting that these drugs should be included from the beginning in neoadjuvant regimens for the treatment of Ewing's sarcoma. The analysis of event-free survival in 158 patients with a 4-year minimum follow-up confirmed that histological response to preoperative chemotherapy is a reliable predictor of outcome in Ewing's sarcoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10050985     DOI: 10.1080/028418698430025

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

Review 1.  Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.

Authors:  Beatrice M Seddon; Jeremy S Whelan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

2.  Histopathologic and Radiologic Assessment of Chemotherapeutic Response in Ewing's Sarcoma: A Review.

Authors:  José M García-Castellano; Nagib Atallah Yordi; Carolina Reyes; John H Healey
Journal:  Sarcoma       Date:  2012-03-01

Review 3.  An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma.

Authors:  David S Shulman; Sarah B Whittle; Didier Surdez; Kelly M Bailey; Enrique de Álava; Jason T Yustein; Adam Shlien; Masanori Hayashi; Alexander J R Bishop; Brian D Crompton; Steven G DuBois; Neerav Shukla; Patrick J Leavey; Stephen L Lessnick; Heinrich Kovar; Olivier Delattre; Thomas G P Grünewald; Cristina R Antonescu; Ryan D Roberts; Jeffrey A Toretsky; Franck Tirode; Richard Gorlick; Katherine A Janeway; Damon Reed; Elizabeth R Lawlor; Patrick J Grohar
Journal:  NPJ Precis Oncol       Date:  2022-09-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.